Nano-drug for treating plateau encephaledema and preparation method thereof
By preparing magnesium complex complex nanoparticles sustained release of citicoline, rhodioside, acetazolamide, and ergothioneine, the problem of insufficient effect of existing drugs in the treatment of plateau brain edema and achieving long-term disease Control and restore blood-brain barrier function, reducing oxidative stress and inflammation in brain tissue.
Patent Information
- Application Number
- CN202411128325.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-16
- Publication Date
- 2024-11-22
AI Technical Summary
The existing drugs have poor effect on treating cerebral edema on the plateau, with a short duration of effect, making it difficult to control the subsequent disease of the continuous plateau exposure, especially in ultra-high altitude areas with poor transportation and medical conditions.
Prepare a nanodrug to enhance the low-pressure and hypoxia adaptability of brain cells and protect dopaminergic by sustained release of citicoline, rhodioside, acetazolamide, and ergothione in the form of magnesium complex nanoparticles. Neurons, which attenuate oxidative stress caused by low pressure and hypoxia, repair brain capillaries and restore blood-brain barriers, inhibit cerebrospinal fluid production to reduce intracranial pressure.
It has achieved long-term maintenance of blood drug concentration, prolonged action time, improved bioavailability, reduced side effects, continuously reduced brain tissue water content, restored blood-brain barrier function, reduced oxidative stress and inflammation, and improved symptoms of plateau brain edema.
Smart Images

Figure CN118987013A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of medicines, and in particular relates to a nano drug for treating high altitude cerebral edema and a preparation method thereof. Background Art
[0002] High-altitude cerebral edema (HACE) is a central nervous system plateau-specific disease that occurs when people who quickly enter plateau areas or move rapidly from plateau areas to higher altitude areas experience severe maladaptation to plateau hypoxia under certain inducements, which in turn causes severe brain dysfunction and severe neuropsychiatric symptoms. The occurrence of HACE is related to many factors, including the length of stay in plateau areas, labor and exercise intensity, temperature, age, gender, drinking, history of plateau diseases, and factors of the body itself. However, the most important risk factors for its occurrence are the speed of the body's ascent, the altitude reached by the body, and the body's sensitivity to plateau hypoxia. HACE is considered to be the terminal stage of acute mountain sickness, with an acute onset, rapid progression, severe symptoms, and a poor prognosis. Therefore, early diagnosis and treatment of HACE are particularly important. Ataxia is the first sign that appears after the occurrence of HACE and is also its main symptom.
[0003] The key event in the occurrence of high-altitude cerebral edema is the destruction of the blood-brain barrier. When the body is exposed to the low-oxygen environment of the plateau, the sympathetic-adrenal system is activated, causing accelerated heartbeat, peripheral vasoconstriction, and increased blood pressure. Hypoxia caused by hypoxia leads to dilation of brain blood vessels. Hypoxia also causes neurons to release excitatory amino acids, promote brain metabolism, and further release vasodilator factors, causing increased blood flow to the brain. The destruction of the blood-brain barrier causes water molecules to leak out of the blood vessels, resulting in vasogenic edema. At the same time, large and small molecular substances in the blood enter the brain tissue through vascular endothelial cells, affecting the normal function of the central nervous system. Continuous hypoxia further aggravates the disorder of the cell membrane sodium-potassium pump, causing the accumulation of water molecules in the cells, leading to cytotoxic edema. The swollen brain tissue compresses the blood vessels, causing a decrease in brain tissue blood supply, further exacerbating brain tissue hypoxia, resulting in a vicious cycle, and ultimately leading to abnormal neuronal function, and then the body shows a series of symptoms of high-altitude cerebral edema.
[0004] At present, this disease mostly occurs in extremely high altitude areas, where transportation and medical conditions are poor. The main treatments include symptomatic treatment, oxygen therapy, drug therapy and hypothermia therapy. However, the current drug treatment is not effective, has a short duration of action, and is difficult to control the subsequent symptoms of continuous plateau exposure. Summary of the invention
[0005] In view of this, the object of the present invention is to provide a nano drug for treating high-altitude cerebral edema and a preparation method thereof, wherein the nano drug can release cytidine, salidroside, acetazolamide, and ergothioneine in a sustained manner. Among them, salidroside enhances the low-pressure and low-oxygen adaptability of brain cells, protects dopaminergic neurons, and synergizes with ergothioneine to reduce the oxidative stress caused by low-pressure and low-oxygen, while cytidine actively repairs brain capillaries and restores the blood-brain barrier, and acetazolamide can penetrate the brain barrier to inhibit the production of cerebrospinal fluid, reduce intracranial pressure, and thus prevent the occurrence of cerebral edema.
[0006] In order to solve the above technical problems, the present invention provides a method for preparing a nano drug for treating high altitude cerebral edema, comprising the following steps:
[0007] S1. Citicoline, acetazolamide and ergothioneine are added to the ammonia solution, and the mixture is stirred thoroughly to obtain an alkaline solution;
[0008] S2. adding magnesium acetate tetrahydrate, salidroside and chitosan oligosaccharide to the acetic acid solution, stirring and mixing thoroughly to obtain an acidic solution;
[0009] S3. The acidic solution obtained in step S2 is slowly dripped into the alkaline solution obtained in step S1 to obtain a mixed solution with a pH value of 4.0-5.0, and then 80-100 v / v% ethanol is added, and the reaction is incubated for 10-20 hours, and the supernatant is removed by centrifugation, and the precipitate is washed and dried to obtain the nanomedicine for treating high altitude cerebral edema. Preferably, the precipitate can be washed with anhydrous ethanol.
[0010] Preferably, in step S1, the feeding ratio of the citicoline, acetazolamide and ergothioneine to the ammonia solution is (7.0-9.0) g: (4.0-5.0) g: (8.75-11.25) g: 100 ml.
[0011] Preferably, in step S2, the feeding ratio of the magnesium acetate tetrahydrate, salidroside and chitosan oligosaccharide to the acetic acid solution is (19.26-21.40) g: (4.0-5.0) g: (4.0-6.0) g: 100 ml.
[0012] Preferably, the volume ratio of the alkaline solution to the acidic solution is 1:1.
[0013] Preferably, in step S1, the concentration of the ammonia solution is 5-10 w / v%.
[0014] Preferably, in step S2, the concentration of the acetic acid solution is 80-90 v / v%.
[0015] Preferably, in step S2, the weight average molecular weight of the chitosan oligosaccharide is 1000-3000, and the degree of deacetylation is 70-95%.
[0016] Preferably, in step S3, the acidic solution is dripped at a rate of 60-120 ml / h.
[0017] The present invention also provides a nano drug prepared by the above preparation method for treating high altitude cerebral edema.
[0018] Compared with the prior art, the present invention has the following beneficial effects:
[0019] The present invention utilizes Mg 2+ As the central atom, with citicoline, acetazolamide, ergothioneine, and salidroside as ligands, chitosan oligosaccharides use the amino and hydroxyl groups on them as connecting ligands, and grow into magnesium complex nanoparticles through reaction. The complex nanoparticles can slowly release ligand molecules in the systemic circulation. Since acetazolamide is very slightly soluble in water and has low bioavailability, it can maintain blood drug concentration for a long time after being made into sustained-release nanoparticles, prevent the liver and kidneys from metabolically decomposing the ligand, prolong the duration of action, and improve bioavailability at the same time, with fewer side effects. While acetazolamide is released, citicoline, ergothioneine, and salidroside can also synergize with acetazolamide to improve HACE symptoms from multiple angles. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 This is a scanning electron microscope photo of the nano drug prepared in Example 1;
[0021] Figure 2 The results of water content determination and Evans blue permeability of brain tissue in animal experiments;
[0022] Figure 3 This is the result of measuring the MDA content in brain tissue in animal experiments;
[0023] Figure 4 The results of SOD activity determination in brain tissue in animal experiments;
[0024] Figure 5 These are the results of measuring IL-1β content in brain tissue in animal experiments. DETAILED DESCRIPTION
[0025] In order to further understand the present invention, preferred embodiments of the present invention are described below in conjunction with examples, but it should be understood that these descriptions are only for further illustrating the features and advantages of the present invention, rather than limiting the claims of the present invention.
[0026] Example 1
[0027] A method for preparing a nano drug for treating high altitude cerebral edema comprises the following steps:
[0028] 1. Add 8.0 g of citicoline, 4.5 g of acetazolamide and 10.5 g of ergothioneine to 100 ml of 8 w / v% ammonia solution, stir and mix thoroughly to obtain an alkaline solution;
[0029] 2. Add 20g of magnesium acetate tetrahydrate, 4.5g of salidroside and 5.0g of chitosan oligosaccharide with a weight average molecular weight of 2000 and a deacetylation degree of 85% into 100ml of 85v / v% acetic acid solution, stir and mix thoroughly to obtain an acidic solution;
[0030] 3. The acidic solution prepared in step 2 was slowly dripped into the alkaline solution prepared in step 1 at a volume ratio of 1:1 at a rate of 100 ml / h to obtain a mixed solution with a pH value of 4.5, and 90 v / v% ethanol was added, and the reaction was incubated for 18 hours, and the supernatant was removed by centrifugation. The precipitate was washed with anhydrous ethanol and dried to obtain a nano drug for treating high altitude cerebral edema ( Figure 1 ).Depend on Figure 1 It can be seen that the particle size of the obtained nanomedicine ranges from 50 to 200 nm, and there is agglomeration between the particles, indicating that adhesion occurred during the reaction growth process. This is due to the interaction between chitosan oligosaccharide and Mg 2+ Linking widens the particle size range, which is beneficial for achieving a sustained-release effect.
[0031] Example 2
[0032] A method for preparing a nano drug for treating high altitude cerebral edema comprises the following steps:
[0033] 1. Add 9.0 g of citicoline, 5.0 g of acetazolamide and 11.25 g of ergothioneine to 100 ml of 10 w / v% ammonia solution, stir and mix thoroughly to obtain an alkaline solution;
[0034] 2. Add 21.40 g of magnesium acetate tetrahydrate, 5.0 g of salidroside and 6.0 g of chitosan oligosaccharide with a weight average molecular weight of 3000 and a deacetylation degree of 95% to 100 ml of 90 v / v% acetic acid solution, stir and mix thoroughly to obtain an acidic solution;
[0035] 3. The acidic solution prepared in step 2 is slowly dripped into the alkaline solution prepared in step 1 at a volume ratio of 1:1 at a rate of 120 ml / h to obtain a mixed solution with a pH value of 5.0, and after adding 100 v / v% ethanol, the reaction is incubated for 20 hours, the supernatant is removed by centrifugation, and the precipitate is washed with anhydrous ethanol and dried to obtain a nanomedicine for treating high-altitude cerebral edema.
[0036] Example 3
[0037] A method for preparing a nano drug for treating high altitude cerebral edema comprises the following steps:
[0038] 1. Add 7.0 g of citicoline, 4.0 g of acetazolamide and 8.75 g of ergothioneine to 100 ml of 5 w / v% ammonia solution, stir and mix thoroughly to obtain an alkaline solution;
[0039] 2. Add 19.26 g of magnesium acetate tetrahydrate, 4.0 g of salidroside and 4.0 g of chitosan oligosaccharide with a weight average molecular weight of 1000 and a deacetylation degree of 70% into 100 ml of 80 v / v% acetic acid solution, stir and mix thoroughly to obtain an acidic solution;
[0040] 3. The acidic solution prepared in step 2 is slowly dripped into the alkaline solution prepared in step 1 at a volume ratio of 1:1 at a rate of 60 ml / h to obtain a mixed solution with a pH value of 4.0. After adding 80 v / v% ethanol, the reaction is incubated for 10 hours, the supernatant is removed by centrifugation, and the precipitate is washed and dried with anhydrous ethanol to obtain a nanomedicine for the treatment of high-altitude cerebral edema.
[0041] Comparative Example 1 (no incubation reaction)
[0042] A nano drug and a preparation method thereof, comprising the following steps:
[0043] 1. Add 8.0 g of citicoline, 4.5 g of acetazolamide and 10.5 g of ergothioneine to 100 ml of 8 w / v% ammonia solution, stir and mix thoroughly to obtain an alkaline solution;
[0044] 2. Add 20g of magnesium acetate tetrahydrate, 4.5g of salidroside and 5.0g of chitosan oligosaccharide with a weight average molecular weight of 2000 and a deacetylation degree of 85% into 100ml of 85v / v% acetic acid solution, stir and mix thoroughly to obtain an acidic solution;
[0045] 3. The acidic solution prepared in step 2 was slowly dripped into the alkaline solution prepared in step 1 at a volume ratio of 1:1 at a rate of 100 ml / h to obtain a mixed solution with a pH value of 4.5. After adding 90 v / v% ethanol, the supernatant was removed by centrifugation, and the precipitate was washed with anhydrous ethanol and dried to obtain the nanomedicine.
[0046] Comparative Example 2 (no magnesium salt)
[0047] A method for preparing a nano drug comprises the following steps:
[0048] 1. Add 8.0 g of citicoline, 4.5 g of acetazolamide and 10.5 g of ergothioneine to 100 ml of 8 w / v% ammonia solution, stir and mix thoroughly to obtain an alkaline solution;
[0049] 2. Add 4.5 g of salidroside and 5.0 g of chitosan oligosaccharide with a weight average molecular weight of 2000 and a deacetylation degree of 85% into 100 ml of 85 v / v% acetic acid solution, stir and mix thoroughly to obtain an acidic solution;
[0050] 3. The acidic solution prepared in step 2 was slowly dripped into the alkaline solution prepared in step 1 at a volume ratio of 1:1 at a rate of 100 ml / h to obtain a mixed solution with a pH value of 4.5. After adding 90 v / v% ethanol, the reaction was incubated for 18 hours, the supernatant was removed by centrifugation, and the precipitate was washed with anhydrous ethanol and dried to obtain the nanomedicine.
[0051] Comparative Example 3 (no chitosan oligosaccharide)
[0052] A method for preparing a nano drug comprises the following steps:
[0053] 1. Add 8.0 g of citicoline, 4.5 g of acetazolamide and 10.5 g of ergothioneine to 100 ml of 8 w / v% ammonia solution, stir and mix thoroughly to obtain an alkaline solution;
[0054] 2. Add 20 g of magnesium acetate tetrahydrate and 4.5 g of salidroside to 100 ml of 85 v / v% acetic acid solution, stir and mix thoroughly to obtain an acidic solution;
[0055] 3. The acidic solution prepared in step 2 was slowly dripped into the alkaline solution prepared in step 1 at a volume ratio of 1:1 at a rate of 100 ml / h to obtain a mixed solution with a pH value of 4.5. After adding 90 v / v% ethanol, the reaction was incubated for 18 hours, the supernatant was removed by centrifugation, and the precipitate was washed with anhydrous ethanol and dried to obtain the nanomedicine.
[0056] Animal experiments
[0057] SPF male Wi star rats were used, with a single body weight of 180-220 g. They were fed with SPF feed and had free access to food and water. The room temperature was 19-24°C.
[0058] Simulated plateau environment experiment: Rats were placed in a large animal experimental cabin simulating plateau environment. The nanomedicines of Examples 1-3 and Comparative Examples 1-3 were first injected through the tail vein. Then, the animals were raised to a simulated altitude of 8000m at a speed of 10m / s for one week. Every 24 hours, the altitude was lowered to 3500m. The experimenters entered the cabin to change water, food and bedding. After the operation, the altitude was raised to 8000m again. During this period, the experimental animals were free to drink water and eat. After the 8000m exposure, the experimenters anesthetized the animals with 4% chloral hydrate intraperitoneally at an altitude of 3500m, and injected 2w / v% Evans blue saline solution into the tail vein. The rats were placed in an incubator and perfused after Evans blue circulated through the body for 1 hour. After that, the cranial cavity was carefully opened and the intact brain tissue was slowly separated. After the experiment, the water content of the brain tissues of all rats was measured, the exudation of Evans blue, and the related antioxidant stress and inflammatory factors were detected. The rats without medication at zero altitude were used as normal controls, and the rats without medication were used as the model group. The results are shown in Figure 2-Figure 5 .
[0059] Depend on Figure 2-Figure 5 It can be seen that the nanoparticles prepared in the embodiment of the present invention can continue to reduce the water content of the brain tissue of HACE rats and reduce the penetration of Evans blue after one week of administration, that is, restore the blood-brain barrier function, and at the same time reduce the oxidative stress level of brain tissue and inhibit inflammation. Comparative Example 1 has no incubation reaction, and cannot form nanoparticles with complete structure and suitable particle size. The formed particles are too small and the action time is too short, so the role of sustained-release ligand cannot be achieved. Comparative Example 2 has no magnesium acetate and cannot be used as Mg 2+ The complex is formed by the central atom, and the only way is to rely on chitosan oligosaccharide to precipitate in ethanol and embed part of the ligand active drug. Acetazolamide is very slightly soluble in both water and ethanol. Therefore, acetazolamide cannot show sustained-release pharmacological activity. 2+ The connection between them, like Comparative Example 1, cannot form nanoparticles with complete structure and suitable particle size. The formed particles are too small and the action time is too short, so the role of sustained-release ligand cannot be achieved.
[0060] The present invention provides a nano drug for treating high-altitude cerebral edema and a method for preparing the same. There are many methods and approaches to implement the technical solution. The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention. All components not specified in this embodiment can be implemented by existing technologies.
Claims
1. A method for preparing a nano drug for treating high altitude cerebral edema, It is characterized in that The steps include: S1. Citicoline, acetazolamide and ergothioneine are added to the ammonia solution, and the mixture is stirred thoroughly to obtain an alkaline solution; S2. adding magnesium acetate tetrahydrate, salidroside and chitosan oligosaccharide to the acetic acid solution, stirring and mixing thoroughly to obtain an acidic solution; S3. Slowly drip the acidic solution into the alkaline solution to obtain a mixed solution with a pH value of 4.0-5.0, add 80-100 v / v% ethanol to the mixed solution, incubate the reaction for 10-20 hours, remove the supernatant by centrifugation, wash the precipitate and dry it to obtain a nanomedicine for treating high-altitude cerebral edema.
2. The preparation method according to claim 1, It is characterized in that In step S1, in the alkaline solution, the feeding ratio of citicoline, acetazolamide, ergothioneine and ammonia solution is (7.0-9.0) g: (4.0-5.0) g: (8.75-11.25) g: 100 ml.
3. The preparation method according to claim 2, It is characterized in that In step S2, in the acidic solution, the feeding ratio of magnesium acetate tetrahydrate, salidroside, chitosan oligosaccharide and acetic acid solution is (19.26-21.40) g: (4.0-5.0) g: (4.0-6.0) g: 100 ml.
4. The preparation method according to claim 2, It is characterized in that In step S3, the volume ratio of the alkaline solution to the acidic solution is 1:
1.
5. The preparation method according to claim 1, It is characterized in that In step S1, the concentration of the ammonia solution is 5-10 w / v%.
6. The preparation method according to claim 1, It is characterized in that In step S2, the concentration of the acetic acid solution is 80-90 v / v%.
7. The preparation method according to claim 1, It is characterized in that In step S2, the weight average molecular weight of the chitosan oligosaccharide is 1000-3000, and the degree of deacetylation is 70-95%.
8. The preparation method according to claim 1, It is characterized in that In step S3, the acidic solution is dripped at a rate of 60-120 ml / h.
9. A nanomedicine for treating high altitude cerebral edema prepared according to the preparation method according to any one of claims 1 to 8.
Citation Information
Cited By
Application of hydrogen-rich water containing salidroside in preparation of medicine for preventing plateau encephaledema
CN119732972A
